Xponance Inc. Has $41.67 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Xponance Inc. lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,130 shares of the medical equipment provider's stock after purchasing an additional 1,803 shares during the period. Xponance Inc.'s holdings in Intuitive Surgical were worth $41,667,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Kesler Norman & Wride LLC increased its stake in shares of Intuitive Surgical by 66.1% during the first quarter. Kesler Norman & Wride LLC now owns 1,776 shares of the medical equipment provider's stock worth $880,000 after acquiring an additional 707 shares during the period. Fidelis Capital Partners LLC raised its stake in Intuitive Surgical by 4.2% during the first quarter. Fidelis Capital Partners LLC now owns 2,380 shares of the medical equipment provider's stock worth $1,225,000 after purchasing an additional 95 shares during the period. Genus Capital Management Inc. increased its position in shares of Intuitive Surgical by 109.1% in the first quarter. Genus Capital Management Inc. now owns 1,789 shares of the medical equipment provider's stock worth $886,000 after acquiring an additional 21,487 shares in the last quarter. MJP Associates Inc. ADV grew its holdings in Intuitive Surgical by 6.1% during the 1st quarter. MJP Associates Inc. ADV now owns 1,118 shares of the medical equipment provider's stock worth $554,000 after acquiring an additional 64 shares in the last quarter. Finally, DMC Group LLC lifted its position in shares of Intuitive Surgical by 54.6% in the 1st quarter. DMC Group LLC now owns 838 shares of the medical equipment provider's stock worth $415,000 after buying an additional 296 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, Director Jami K. Nachtsheim sold 2,400 shares of the business's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the transaction, the director directly owned 6,371 shares of the company's stock, valued at approximately $3,312,920. The trade was a 27.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gary Loeb sold 1,700 shares of the company's stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $513.18, for a total value of $872,406.00. Following the transaction, the executive vice president directly owned 2,245 shares of the company's stock, valued at $1,152,089.10. This represents a 43.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,998 shares of company stock valued at $2,611,577 in the last three months. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Trading Down 2.7%

NASDAQ:ISRG traded down $13.99 during mid-day trading on Friday, hitting $512.06. 2,951,229 shares of the company's stock traded hands, compared to its average volume of 1,679,961. The firm has a 50 day moving average of $538.20 and a two-hundred day moving average of $536.86. Intuitive Surgical, Inc. has a 12 month low of $413.82 and a 12 month high of $616.00. The firm has a market capitalization of $183.53 billion, a price-to-earnings ratio of 75.08, a price-to-earnings-growth ratio of 5.58 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period last year, the firm posted $1.50 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ISRG. Piper Sandler lowered their price objective on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Truist Financial decreased their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on shares of Intuitive Surgical and gave the stock a "buy" rating in a research note on Monday, April 14th. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a report on Thursday, June 5th. Finally, Royal Bank Of Canada reduced their target price on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus target price of $592.59.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.